Friday, December 15, 2017 7:06:00 PM
Disclaimer: All information below and in prior posts linked at the bottom was taken from financial filings filed with the SEC. Some calculations and assumptions needed to be made on my part.
As of September 30th 2017
Shares Outstanding: 10,539,057
Warrants: 6,517,500
Options: 455,000
Fully Diluted Share Count: 17,511,557
Warrants:
A: 214,433 Exercisable @ $1.20 Expire on 1/13/2020
C: 110,683 Exercisable @ $6.00 Expire on 1/13/2020
C: 313,750 Exercisable @ $4.00 Expire on 1/13/2020
D: 297,500 Exercisable @ $9.00 Expire between 7/16/2020 & 8/13/2020 and 8/19/2020 & 9/9/2020
D: 312,500 Exercisable @ $4.00 Expire between 7/16/2020 & 8/13/2020 and 8/19/2020 & 9/9/2020
E: 261,100 Exercisable @ $15.00 Expire between 10/01/2020 and 11/12/2020 and 11/30/2020 and 12/09/2020
E: 187,000 Exercisable @ $4.50 Expire between 10/01/2020 and 11/12/2020 and 11/30/2020 and 12/09/2020
F: 290,833 Exercisable @ $7.20 Expire on 8/11/2021
F: 292,500 Exercisable @ $4.00 Expire on 8/11/2021
A-1: 418,750 Exercisable @ $1.20 Expire on 3/9/2020
C-1: 2,083 Exercisable @ $6.00 Expire on 01/13/2020
D-1: 416,667 Exercisable @ $9.00 Expire between 8/19/2020 & 9/9/2020
E-1: 418,750 Exercisable @ $15.00 Expire between 6/16/2020
F-1: 416,667 Exercisable @ $7.20 Expire on 8/11/2021
Pipe: 653,187 Exercisable @ $6.00 Expire on 8/11/2021
Broker: 65,327 Exercisable @ $4.80 Expire on 8/11/2021
June 26, 2017 warrants: 1,653,924 Exercisable @ $3.97 Expire in 5 years
*In June of 2017 series C, D, E, & F warrants were repriced. From the latest 10Q found HERE it doesn’t seem that all of them were repriced. That is why there are two listings for each of these series of warrants on the above breakdown. It also did not seem that any or Eastern Capital’s warrants were repriced. I have an email out to IR to confirm if my assumptions are correct in that not all of these warrants were repriced.
All of the above warrants are subject to blockers so can only be exercised if doing so would not put the holder over a certain percentage of ownership. That information can be found in past posts as it has not changed. Prior to the offering in June a lot of the warrants were at that point that they could not be exercised without exceeding maximum allowable ownership. With the latest offering and subsequent increase in outstanding shares I believe now more of these warrants can be exercised. Still, I don’t believe the number is substantial enough to matter. Feel free to calculate it if you wish.
Of the outstanding 10,539,057 shares ~4,185,768 are held by insiders and institutions. This leaves a public float of ~6,353,289. That is insanely small. This is the reason the price has been fluctuating on such low volume. The price swings will continue on the low volume until we get some substantial news. Any comments of the share price being driven up just so “they” dump shares are, at this point, not backed by any evidence or volume. If a dump does happen it will be painfully obvious and then reflected in SEC filings.
Good luck everyone. I encourage you all to do your own DD.
Below are links to my prior posts on the warrant situations if you would like to see my initial DD:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=131802193 Post Date: 5/31/2017
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=125189288 Post Date: 9/15/2016
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121105185 Post Date: 3/10/2016
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=119149223 Post Date: 12/14/2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118740621 Post Date: 11/24/2015
Friends don't let friends place market orders
Recent MRKR News
- Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors • GlobeNewswire Inc. • 08/28/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:47:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:39:13 PM
- Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 08/14/2024 08:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 11:12:59 AM
- Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma • GlobeNewswire Inc. • 08/12/2024 11:00:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:05:47 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 10:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:03:21 PM
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM